ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Pluripotent Stem Cell Line ESI-053. IMS001 is an investigational, allogeneic, MSC product derived from a human embryonic stem cell line. It is assumed to be the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA for patients with MS. November 30, 2021, … Continue reading AgeX Therapeutics’ Licensee ImStem Biotechnology Does First U.S. Multiple Sclerosis Patient with IMS001